This article is more than 5 years old. Information may no longer be current.
Bonesupport receives CE mark for injectable ceramic bone substitute
Click Here to Manage Email Alerts
Bonesupport announced that Cerament|G has received CE mark for the promotion and protection of bone healing being jeopardized by infection.
According to a company press release, Cerament|G is the first injectable antibiotic eluting, osteoconductive ceramic bone substitute to receive CE mark. Designed to fill bone gaps and voids and augment hardware and bone fractures during surgical procedures, Cerament|G remodels into healthy native bone within 6 to 12 months. With an elution profile and a focused local delivery of gentamicin, the device is intended to prevent colonization of sensitive microorganisms, which protects bone healing, particularly in challenging cases of deep bone infection.
“Osteomyelitis affects 150 million people worldwide each year,” Lloyd Diamond, CEO of Bonesupport, stated. “Many of these people suffer from deep bone infections and face years of antibiotic therapy, multiple surgical interventions and ultimately the threat of amputation. Expanding the Cerament portfolio to include this first in class antibiotic eluting formula provides a critical bone healing treatment option for the management of this debilitating condition, and continues our commitment to improve outcomes for physicians and patients.”